{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:24:08Z","timestamp":1791188648355,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2011,9,23]],"date-time":"2011-09-23T00:00:00Z","timestamp":1316736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:sec><jats:label\/><jats:p>Eur J Clin Invest 2012; 42 (5): 463\u2013469<\/jats:p><\/jats:sec><jats:sec><jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Myeloperoxidase (MPO) is involved in a multitude of inflammatory processes involving oxidative modification of soluble components and cellular surfaces. Thus, MPO plays a key role in promoting atherosclerosis via oxidative stress by modification of both high\u2010 and low\u2010density lipoprotein and production of other bioactive molecules. A polymorphism (MPO 463G&gt;A, rs2333227) results in different expression rates of MPO. We aimed to assess whether MPO could be of clinical use as a risk marker for vascular disease in a high\u2010risk group.<\/jats:p><jats:p><jats:bold>Material and methods\u2002<\/jats:bold> Plasma MPO levels of 406 patients suffering from peripheral arterial disease (PAD) were measured on an Abbott Architect i2000sr and grouped into patients with high (&gt;115\u2003ng\/mL) and low (&lt; 115\u2003ng\/mL) MPO levels. Genotyping of rs2333227 was performed on an ABI TaqMan 7900HT RT\u2010PCR thermocycler.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> The relative risk of major adverse cardiovascular events (MACE) for patients with high plasma MPO is 1\u00b72 (95%CI: 1\u00b7038\u20131\u00b7377, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705), initial event\u2010free periods in male patients are significantly longer in patients with MPO &lt;115\u2003ng\/mL (mean\u2003=\u2003875\u2003days compared with mean\u2003=\u2003734\u2003days, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705) In smokers, an increased hazard ratio was computed for patients with high MPO levels (HR\u2003=\u20033\u00b7127, 95%CI: 1\u00b7258\u20137\u00b7772, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030\u00b705). Effects of MPO [\u2010463A] allele on initial MACE\u2010free intervals did not persist after multivariate analysis.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Hence, we suggest consideration of plasma MPO for risk stratification of MACE in patients with PAD. In contrast, MPO\u2010463G&gt;A is not an independent risk factor for MACE in patients suffering from PAD.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2362.2011.02601.x","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T03:54:57Z","timestamp":1314849297000},"page":"463-469","source":"Crossref","is-referenced-by-count":20,"title":["Plasma myeloperoxidase level and peripheral arterial disease"],"prefix":"10.1111","volume":"42","author":[{"given":"Helmuth","family":"Haslacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Perkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gruenewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Exner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Endler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Scheichenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,9,23]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2009.2538"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1204697"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(99)00146-5"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112965"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2010.04.008"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800086-JLR200"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/tx9003775"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-007-0027-2"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hco.0000231402.87232.aa"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2008.tb00012.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/135625"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2009.126029"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.24.14412"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(97)00089-1"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.7.2730.2730_2730_2737"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31803068b1"},{"key":"e_1_2_8_18_2","first-page":"5001","article-title":"Myeloperoxidase genetic polymorphism and lung cancer risk","volume":"57","author":"London SJ","year":"1997","journal-title":"Cancer Res"},{"key":"e_1_2_8_19_2","first-page":"644","article-title":"Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant\u2013463A of the myeloperoxidase gene","volume":"60","author":"Cascorbi I","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_8_20_2","first-page":"181","article-title":"Association of the myeloperoxidase \u2010463G\u2010\u2010>a polymorphism with lung cancer risk","volume":"9","author":"Le Marchand L","year":"2000","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.3.341"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1998.6977"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.9.1284"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021771"},{"key":"e_1_2_8_25_2","first-page":"S1","article-title":"Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter\u2010Society Consensus (TASC)","volume":"31","author":"Dormandy JA","year":"2000","journal-title":"J Vasc Surg"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(00)00804-4"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000095267.24234.00"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040296"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2009.02234.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2007.101568"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp310"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.100.13.1481"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X08101999"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035003"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000090690.67322.51"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm587"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2011.02601.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2011.02601.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:27:41Z","timestamp":1698712061000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2011.02601.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,23]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1365-2362.2011.02601.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2011.02601.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"value":"0014-2972","type":"print"},{"value":"1365-2362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,23]]}}}